Drug intelligence / Profile preview

miR-140-3p antagomir

Development stage
Preclinical
Modality
Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intracerebroventricular
01

Overview

miR-140-3p antagomir is a chemically modified, single-stranded antisense oligonucleotide research tool designed to silence the biological activity of microRNA-140-3p (miR-140-3p). These molecules typically feature phosphorothioate modifications to enhance metabolic stability and a cholesterol conjugation to facilitate cellular uptake. In preclinical models, miR-140-3p antagomirs have been utilized to study the regulation of genes such as KIF5A in spinal muscular atrophy (SMA) and SUZ12 in acute myeloid leukemia (AML). By binding with high affinity to the mature miR-140-3p sequence, the antagomir prevents the microRNA from binding to its target mRNAs, thereby modulating downstream signaling pathways involved in neurodegeneration, cardiac function, and oncogenesis.

Other names
antagomir-140-3pantagomir140-3pantagomir 140-3pmicroRNA-140-3p antagomirmicroRNA140-3p antagomirmicroRNA 140-3p antagomir

Beyond the preview

Go deeper on miR-140-3p antagomir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on miR-140-3p antagomir.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call